Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
safotibant
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Topical, Ophthalmic
01
Overview
Safotibant (FOV2304) is a small molecule bradykinin B1 receptor antagonist developed for the topical treatment of diabetic macular edema and other forms of macular edema. It was originally developed by Fovea Pharmaceuticals and later by Sanofi. The drug acts by selectively blocking the bradykinin B1 receptor, which is implicated in inflammation and increased vascular permeability in retinal diseases. Safotibant was investigated as an ophthalmic solution administered topically to the eye. Clinical trials included phase I and II studies assessing its safety and efficacy for center-involving clinically significant macular edema associated with diabetic retinopathy[3][5][7]. Development for this indication has been discontinued[5].
- Other names
- safotibantFOV 2304FOV2304FOV-2304
02
Targets
BDKRB1 (Bradykinin Receptor B1)
Beyond the preview
Go deeper on safotibant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on safotibant.